Albert Bourla, chief executive officer of Pfizer Inc., speaks during China Development Forum (CDF) 2023 at Diaoyutai State Guesthouse on March 25, 2023 in Beijing, China.
Lintao Zhang | Getty Images
Pfizer on Wednesday forecast 2024 revenue and profit below Wall Street expectations, sending its shares down 6% in premarket trading even as it raised cost-cut target by $500 million.
The U.S. drugmaker expects its annual revenue to be in the range of $58.5 billion to $61.5 billion compared with analysts’ average estimate of $63.17 billion, according to LSEG data. It includes the contribution from sales of Seagen’s products.
The company also forecast adjusted profit in the range of $2.05 to $2.25 per share, lower than analysts’ expectation of $3.16.
Sales of Paxlovid and the vaccine Pfizer makes with German partner BioNTech had boosted revenue over the last two years, helping it generate more than $100 billion in 2022.
But a drop in annual vaccination rates and demand for the treatments have forced the company to launch a program in October to cut jobs and expenses to save as much as $3.5 billion.
The company, which employs roughly 83,000 employees globally, in November cut 500 jobs at its Sandwich, Kent site in the UK.
Image and article originally from www.cnbc.com. Read the original article here.